Zeitschrift für Blut und Lymphe

Commentary on TP53 Mutated Myeloid Malignancies and Their Treatment Strategy

Abstract

Yasuhito Nannya*

TP53-mutated myeloid neoplasms are currently recognized as a distinct entity based on the findings that TP53-mutated myeloid neoplasms have highly distinctive clinical and genetic features: Cases with mutations in this gene tend to have genomic instability, as represented by the complex karyotype almost inevitably involving -5/del(5q), a lower number of other driver mutations, and a dismal clinical outcome that is resistant to most treatments, including hematopoietic stem cell transplantation.